RBC Capital lowered the firm’s price target on Bausch Health to $8 from $9 and keeps a Sector Perform rating on the shares ahead of its Q3 results. The analyst is citing adverse FX moves while also adjusting the firm’s model for Xifaxan U.S. scripts estimated to be slightly down in Q3 after growth in the first half of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHC:
